Swiss Re says GLP-1 drugs could reduce US mortality by up to 6.4%

Core Viewpoint - Swiss Re indicates that the widespread use of GLP-1 drugs for obesity treatment could lead to a reduction in the annual death rate by up to 6.4% in the United States by 2045 [1] Group 1 - The potential impact of GLP-1 drugs on public health is significant, suggesting a proactive approach to obesity management could yield substantial benefits [1]